Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sangamo BioSciences Reports First Quarter 2010 Financial Results
Press Release Source: Sangamo BioSciences, Inc. On Monday May 3, 2010, 4:01 pm EDT
RICHMOND, Calif., May 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq:SGMO - News) today reported first quarter 2010 financial results and accomplishments.
For the first quarter ended March 31, 2010, Sangamo reported a consolidated net loss of $4.0 million, or $0.09 per share, compared to a net loss of $6.8 million, or $0.17 per share, for the same period in 2009. As of March 31, 2010, the company had cash, cash equivalents, marketable securities and interest receivable of $77.0 million.
Revenues for the first quarter of 2010 were $6.6 million, compared to $3.2 million for the same period in 2009. First quarter 2010 revenues were from the Company's collaboration agreements with Sigma-Aldrich Corporation and Dow AgroSciences, enabling technology agreements and research grants. The revenue recognized for the first quarter of 2010 consisted of $6.2 million in collaboration and enabling technology agreements and $449,000 in research grants. The increase in collaboration agreement revenues was primarily due to the license payment received from Sigma-Aldrich as part of its agreement with the Company which was expanded in the fourth quarter of 2009 and provides Sigma exclusive rights to develop and distribute zinc finger DNA-binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals. The payment is being recognized as revenue ratably through July 2010, the remaining period of the Company's original research collaboration with Sigma-Aldrich.
Research and development expenses were $7.4 million for the first quarter of 2010, compared to $7.3 million for the same period in 2009. Research and development expenses for the first quarter of 2010 were primarily related to our clinical trials of SB-509 for diabetic neuropathy and SB-728-T for HIV/AIDS. General and administrative expenses were $3.3 million for the first quarter of 2010, compared to $2.9 million for the same period in 2009. The increase in general and administrative expenses was primarily due to increased personnel costs, including non-cash employee stock-based compensation, and professional fees.
Total operating expenses for the first quarter of 2010 were $10.7 million, compared to $10.2 million for the same period in 2009.
Net interest income and other income was $25,000 for the first quarter of 2010, compared to $193,000 for the same period in 2009. The decrease was due to lower interest rates on investments.
Recent Highlights
•Initiation of New Clinical Trials; Phase 2b study in Diabetic Neuropathy and Phase 1 Trial in Brain Cancer (Glioblastoma) with City of Hope: In January 2010, Sangamo initiated a Phase 2b trial of SB-509 in subjects with moderately severe diabetic neuropathy. The Juvenile Diabetes Research Foundation International (JDRF) also renewed its support for this program and will provide up to $3.0 million of funding for the trial. Sangamo's double blind, repeat-dosing, placebo-controlled Phase 2b study, SB-509-901, is designed to finalize dose, schedule and primary and secondary approvable endpoints for pivotal Phase 3 trials. Sangamo's collaborators at City of Hope also initiated a Phase 1 clinical trial of SB-313, a cytotoxic T-cell made glucocorticoid resistant using ZFN mediated gene-editing, that is being evaluated in subjects with recurrent or refractory glioblastoma.
•Presentation of Preliminary Data from Sangamo's Phase 1 Safety Trial of SB-728-T for HIV/AIDS: In January 2010, preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented at the Keystone Symposium Session "HIV Biology and Pathogenesis." Sangamo's collaborator, Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, presented the data as an invited speaker in an NIAID Workshop entitled "The Next Challenge: Elimination of HIV Reservoirs." Dr. June described data from a single HIV-positive subject treated with SB-728-T who, as part of the study, began a structured treatment interruption (STI) from his antiviral drug therapy after being treated with CCR5 negative ZFN-modified T-cells. During the monitoring period, the subject had stable levels of ZFN-modified T-cells which were well-tolerated and stable CD4+ T-cell counts. Interestingly, while the subject's viral load increased as expected during the STI period, the timing of the increase was somewhat delayed. Biopsy samples demonstrated that ZFN-modified cells appeared to circulate and traffic normally.
•Appointment of Two New Members of the Sangamo Board of Directors, Stephen G. Dilly, M.B.B.S, Ph.D. and William R. Ringo as Chairman of the Board: Dr. Dilly, who is currently President and CEO of APT Pharmaceuticals, Inc., a specialty drug company, was appointed to the board of directors effective March 31, 2010. Dr. Dilly has been closely associated with the development and launch of marketed drugs for many therapeutic areas in his previous senior executive positions in drug development at Chiron BioPharma, Genentech Inc. and SmithKline Beecham in the U.K. Mr. Ringo, who recently retired as Senior Vice President of Business Development, Strategy and Innovation at Pfizer Inc. where he had responsibility for guiding Pfizer's overall strategic planning and business development activities, was appointed as Chairman of the Sangamo Board of Directors on April 16, 2010.
Conference Call
Sangamo will host a conference call today at 5:00 p.m. ET, which will be open to the public. The call will also be webcast live and can be accessed via a link on the Sangamo BioSciences website in the Investor Relations section under "Events and Presentations" http://investor.sangamo.com/events.cfm. A replay of the webcast will also be available for two weeks after the call. During the conference call, the company will review these results, discuss other business matters, and provide guidance with respect to the rest of 2010.
The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 70476823. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on May 3, 2010 to 11:59 p.m. ET on May 10, 2010. The conference call replay numbers for domestic and international callers are 800-642-1687 and 706-645-9291, respectively. The conference ID number for the replay is 70476823.
4:17PM Sangamo BioSci misses by $0.09, misses on revs (SGMO) 6.45 +0.29 : Reports Q1 (Mar) loss of $0.09 per share, $0.09 worse than the Thomson Reuters consensus of ($0.00); revenues rose 106.2% year/year to $6.6 mln vs the $11.2 mln consensus
I'm a new investor in this issue and it appears the company is well positioned with several excellent directions the Zinc Finger technology can take it.
Is there a primary or more active Forum for this stock? I see several msgs per day on the Yahoo BTIM board. Others?
rjw
KC MO
7 Firms Developing RNAi Drugs
http://www.thestreet.com/story/10713267/2/7-firms-developing-rnai-drugs.html
Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 1 Safety Trial of SB-728-T for HIV/AIDS
--First Human Data from ZFN Clinical Program --ZFN-Modified Cells Well Tolerated and Able to Expand
RICHMOND, Calif., Jan 19, 2010 /PRNewswire via COMTEX/ -- Sangamo BioSciences, Inc. announced today that preliminary data from the University of Pennsylvania investigator sponsored Phase 1 safety study of Sangamo's zinc finger nuclease (ZFN) based product, SB-728-T, for HIV/AIDS were presented on Friday, January 15, 2010 at the Keystone Symposium Session "HIV Biology and Pathogenesis." Sangamo's collaborator, Carl June, M.D., Director of Translational Research at the Abramson Family Cancer Research Institute at the University of Pennsylvania School of Medicine, presented the data as an invited speaker in an NIAID Workshop entitled "The Next Challenge: Elimination of HIV Reservoirs."
"While only representative of a single individual in the trial, these data are very exciting," said Dr. June. "They demonstrate that the ZFN-modified T-cells were well tolerated by the body and persisted in the circulation at stable levels for the duration of our monitoring. In fact, we calculate that more ZFN-modified cells were present at 20 weeks than were initially infused. Total CD4+ T-cell counts were also stable during this time. Interestingly, we also observed ZFN-modified cells in the gut associated lymphoid tissue (GALT) which is a major reservoir of immune cells and a critical reservoir of HIV infection and suggests that the modified cells are functioning and trafficking normally in the body."
Dr. June described data from a single HIV- positive subject treated with SB-728-T who, as part of the study, began a structured treatment interruption (STI) from his antiviral drug therapy four weeks after SB-728-T treatment. Twelve weeks later, the STI ended and the subject resumed antiviral therapy. During the study, the subject's CD4+ T-cell count, the number of circulating ZFN-modified cells and viral loads were measured periodically. In addition, rectal biopsies were taken prior to treatment and at the end of the STI period to monitor levels of CD4+ and ZFN-modified T-cells in the GALT.
The subject entered the STI period with stable CD4+ and ZFN-modified T-cell levels and an undetectable viral load. Viral load was monitored with biweekly testing and it was observed that the subject experienced a delay in the return of virus, which was first detectable at six weeks post STI initiation. Previous studies have shown that in subjects undergoing an STI, the average time to detection of an increase in viral load is two to four weeks. At twelve weeks post STI, in accordance with the trial protocol, the subject resumed antiretroviral medication and his viral load decreased. During the monitoring period, the subject continued to demonstrate stable CD4+ T-cell counts and stable levels of ZFN-modified T-cells. In rectal biopsy samples taken at the end of the STI period, ZFN-modified cells were found in GALT suggesting that these cells circulate and traffic normally.
"These are the first human data from a ZFN-based therapeutic and, although preliminary, are very encouraging and recapitulate observations that we have made in preclinical studies," stated Dale Ando, Sangamo's vice president of therapeutic development and chief medical officer. "Importantly, ZFN-modified cells expanded over the period that we monitored the subject and were well tolerated. As expected, the subject's viral load increased during the STI. However, the kinetics of this subject's viral rebound was delayed. Presence of ZFN-modified cells in the GALT, an important HIV reservoir, demonstrates that we are achieving our pharmacologic biodistribution target. GALT HIV persistence in CD4+ T-cells is the reason that HIV is not eradicated in patients who are fully suppressed on highly active anti-retroviral treatment, or HAART. Ultimately, having a protected CD4+ T-cell population in the GALT may be extremely important in combating this disease.
"Our ZFN-based technology provides a totally new approach to HIV/AIDS with the aim of providing a reservoir of functional T-cells that are resistant to infection by HIV and available to fight opportunistic infections, and these data are an early indication that this may be possible."
About SB-728-T
SB-728-T is a cell product based on Sangamo's ZFN technology. CD4+ T-cells are removed from the subject's blood and treated with Sangamo's ZFNs designed to modify the DNA sequence encoding the CCR5 gene. This modification can occur directly in T-cells with only a brief exposure to the ZFNs. Once the CCR5 gene is modified, the gene is permanently disrupted in these cells.
CCR5 is a co-receptor that enables HIV to enter and infect cells of the immune system. About ten years ago, it was observed that individuals carrying a natural mutation of their CCR5 gene, CCR5-delta32, were highly resistant to infection by HIV. These individuals, lacking a functional CCR5 (approximately 1-2% of the general population), are immunologically "normal". A variety of small molecule and antibody antagonists of CCR5 have been tested and developed as potential therapeutic agents for the treatment of HIV infection. In addition, there is a recent report of a patient who had both HIV and leukemia and received a bone marrow transplant from a donor carrying the CCR5 mutation. After the successful bone marrow transplant, HIV treatment was discontinued and the virus could not be found in the circulating blood several months after the procedure.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in a Phase 2b clinical trial for evaluation of safety and clinical effect in patients with diabetic neuropathy and a Phase 2 trial in ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a treatment for HIV/AIDS and another Phase 1 trial to evaluate safety and clinical effect of a treatment for recurrent glioblastoma multiforme. Other therapeutic development programs are focused on neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the clinical trials of SB-728-T, tolerability and efficacy of SB 509-728-T, research and development of novel ZFP TFs and ZFNs and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the small size of the data set, completion of stages of the SB-728-T clinical trials, whether the SB-728-T clinical trials will validate and support tolerability and efficacy of SB-728-T, technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
Gotta luv the Phase 2 progress! eom
Sangamo BioSciences Advances ZFP Therapeutic(TM) Pipeline
Initiation of Two New Clinical Trials and Renewed JDRF Funding
RICHMOND, Calif., Jan 11, 2010 /PRNewswire via COMTEX/ -- Sangamo BioSciences, Inc. announced the initiation of two new clinical trials of ZFP Therapeutics, a Phase 2b study in diabetic neuropathy (DN) and a Phase 1 trial in glioblastoma, as well as the renewal of $3.0 million in funding for the Phase 2b trial by the Juvenile Diabetes Research Foundation International (JDRF). Edward Lanphier, Sangamo's president and CEO, will provide an update on the company's ZFP Therapeutic(TM) pipeline and an overview of the company's business strategy and objectives for 2010 during his presentation at the 28th Annual J.P. Morgan Healthcare Conference at 2:30 pm PT, on Wednesday, January 13, 2010.
"We enter 2010 with a strong balance sheet and a robust clinical pipeline," said Mr. Lanphier. "With the initiation of these two new clinical trials, we continue to increase the value, maturity and visibility of our novel drug development platform."
"We are developing our lead therapeutic, SB-509, for neurological indications including DN and ALS. The data generated to date in DN, our most advanced program, provide direct histologic evidence of nerve regrowth with SB-509 treatment and a mechanistic proof of concept for its neuroregenerative effects. Our enthusiasm for the potential and importance of this drug is shared by JDRF who, after extensive review of the clinical data, has committed to fund a further $3.0 million of development costs for this new Phase 2b trial. While we continue active discussions with potential corporate partners, timely initiation of this trial enables us to maximize the future value of this program. Finally, the Phase 1 glioblastoma trial is our third ZFP Therapeutic and the second zinc finger nuclease (ZFN)-based program to enter the clinic and we are pleased to have achieved this significant milestone."
"Neuropathy is a significant complication of diabetes and represents a major unmet medical need, so developing better treatments would be a tremendous near-term benefit for people with diabetes," stated Alan Lewis, Ph.D., President and Chief Executive Officer of JDRF. "JDRF is excited to move this partnership forward, particularly as it involves a drug candidate designed to harness the body's own regenerative potential to address the nerve loss characteristic of neuropathy."
The Phase 1 glioblastoma trial will be initiated by Sangamo's collaborators at City of Hope and is designed to evaluate the safety and tolerability of a modified CD8+ cytotoxic T lymphocyte (CTL) product that has been made resistant to glucocorticoid steroids using Sangamo's ZFP nuclease ZFN-based technology. The study will accrue subjects with recurrent/refractory malignant glioblastoma multiforme (GBM). The US Food and Drug Administration (FDA) has reviewed and accepted an Investigational New Drug (IND) application to initiate this open-label, multi-dosing Phase 1 clinical trial.
"We look forward to initiating this study to evaluate a promising therapeutic approach for the treatment of malignant brain tumors for which there are currently few effective therapeutic options after surgery," said Michael C.V. Jensen, M.D., Associate Chair, Department of Cancer Immunotherapeutics and Tumor Immunology, City of Hope. "In collaboration with Sangamo, we have successfully generated engineered T-cells that can destroy glioblastoma tumor cells in animals in the presence of glucocorticoids. Treatment of recurrent GBM with modified CTLs, an otherwise promising approach for this cancer, is rendered ineffective by the use of glucocorticoids to control inflammation of the brain due to the tumor and surgery. The ZFN-modification of the glucocorticoid receptor (GR) in our engineered CTLs protects the cells from the effects of steroids, which would normally inhibit T-cell function, but does not alter their cytolytic or tumor-killing properties."
"Our significant clinical, commercial and financial progress in 2009 provides us with a solid foundation upon which to build in 2010," commented Mr. Lanphier. "In the next twelve months, we expect to have final data from two Phase 2 clinical trials of SB-509, one in severe DN (SB-509-701) and one in ALS (SB-509-801). In addition, we expect to have preliminary data from our two ongoing Phase 1 trials of our ZFN-based Therapeutic, SB-728-T for the treatment of HIV/AIDS. We look forward to advancing our clinical pipeline as well as participating in the successful commercial expansion of our ZFP technology through our partnerships in plant agriculture and in the growing area of cell line engineering and transgenic animal model production."
Detail on Phase 2b Trial (SB-509-901) in Diabetic Neuropathy
Sangamo's double blind, repeat-dosing, placebo controlled Phase 2b study, SB-509-901, is designed to finalize dose, schedule and primary and secondary endpoints for pivotal Phase 3 trials. The trial will accumulate data on approvable endpoints including Neurological Impairment Score in the Lower Limb (NIS-LL), nerve conduction velocity in the sural nerve (sNCV), as well as quality of life assessments (QOL) and intraepidermal nerve fiber density (IENFD). The study will involve a total of 150 subjects who will be randomized 1:1 between placebo and treatment groups and is powered to detect statistical significance for improvements in sNCV. Inclusion criteria for the trial are based upon accumulated data from Sangamo's earlier Phase 1 and Phase 2 clinical trials in subjects with DN.
"The body of clinical data obtained in previous trials of SB-509 has enabled us to design a very focused Phase 2b study that will accrue subjects that we believe are most likely to show a significant response to SB-509 over the 180 day test period," commented Dale Ando, Sangamo's chief medical officer and vice president of therapeutics. "The data generated to date also demonstrated that SB-509 treatment resulted in statistically significant increases in nerve fiber density, nerve regeneration and an improvement in clinical outcomes such as NIS-LL and sNCV. Information collected in our Phase 2b trial will allow us to confirm eligibility criteria and primary clinical endpoints for future Phase 3 trials."
SB-509 is an injectable plasmid encoding a DNA-binding zinc finger DNA-binding protein (ZFP) transcription factor (ZFP TF) designed to upregulate the endogenous expression of the gene encoding vascular endothelial growth factor (VEGF-A). VEGF-A has been demonstrated to have direct angiogenic, neurotrophic and neuroprotective properties. Data from Phase 1 and Phase 2 clinical trials in subjects with DN have demonstrated a direct neuroregenerative effect of SB-509 treatment that resulted in a statistically significant (p value = 0.02) increase in IENFD in subjects with DN. IENFD is a validated, direct histologic measurement of small unmyelinated sensory nerve fibers in the skin, the primary sensory nerves involved in DN. IENFD also correlates with neuropathy severity in diabetes, nerve fiber densities derived from sural nerve biopsies and levels of vascular endothelial growth factor-A (VEGF-A). In subjects with more severe neuropathy, as judged by their baseline IENFD, a greater nerve regrowth response to SB-509 treatment was observed compared to regrowth responses in placebo-treated subjects. In addition, subgroup analyses using baseline severity of disease for both neurologic and vascular disease as a selection criterion demonstrated that SB-509 treatment resulted in correlative, clinically-relevant improvements in NIS-LL and sNCV in subjects with moderate to severe disease.
Detail on Phase 1 Trial Objective in Glioblastoma Multiforme (GBM)
The Phase 1 trial is a repeat-dosing, open-label trial of a modified CD8+ cytotoxic T lymphocyte (CTL) product that has been made resistant to glucocorticoid steroids using Sangamo's ZFP nuclease ZFN-based technology. The study is designed to assess safety and tolerability of treatment in approximately 10 subjects with recurrent or refractory malignant GBM. In addition, data will be collected on the survival of the infused, modified CTLs as well as tumor response and survival. The trial will be conducted exclusively at City of Hope.
About Diabetic Neuropathy
Diabetic neuropathy is a progressive degenerative disease that is one of the most frequent complications of diabetes, affecting between 14 and 16.5 million Americans in 2007. High blood glucose levels lead to nerve damage over time, primarily affecting peripheral nerves. Symptoms include numbness, tingling sensations and pain particularly in the toes or feet, which gradually evolve to loss of sensation and motor function as nerve damage progresses. Ulcers and sores may appear on numb areas of the foot as pressure wounds or injuries go unnoticed. Despite palliative treatment, these areas of trauma frequently become infected and this infection may spread to the bone, necessitating amputation of the leg or foot. More than 60 percent of non-traumatic lower-limb amputations in the United States occur among people with diabetes. In 2004, this translated to approximately 71,000 amputations. The Centers for Disease Control estimates that from 1980 through 2007, the number of Americans with diabetes increased from 5.6 million to 23.6 million and that of those about 60 percent to 70 percent have mild to severe forms of neuropathy.
About Glioblastoma Multiforme (GBM)
An estimated 40,000 tumors are diagnosed each year; about 22,000 of these will be malignant. Of these primary brain tumors, gliomas are the most common type, approximately 20,000 cases are diagnosed and 13,000 glioma-related deaths occur annually in the US. Glioblastoma multiforme (GBM), a type of glioma, is rapidly progressive and nearly uniformly lethal. Currently, malignant glioma is managed through a combination of chemotherapy, surgery and radiation if the location and size of tumor allow these treatments. With modern combination therapy, the mean duration of survival has increased to 82 weeks, although 5-year survival rates have only increased from 3% to 6%. Approximately 80% of recurrent tumors arise from remnants of the original incompletely resected tumor. The median survival of recurrent glioblastoma multiforme patients that are eligible to be treated with re-resection is 36 weeks. Due to the location of these tumors in the central nervous system, current treatments often exacerbate the already severe morbidities. Immunotherapeutic strategies, such as anti-VEGF and chimaeric T cell receptors, are increasingly being used since they are very tumor specific and limit side effects in the recurrent disease setting.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to clinical trials of ZFP Therapeutics in diabetic neuropathy and glioblastoma, the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP technology platform to specific human disease as well as plant agriculture, high value research reagents and cell-line engineering, establishing strategic partnerships for SB-509 and other therapeutic programs. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation, completion and outcome of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See Sangamo's SEC filings, and in particular, the risk factors described in Sangamo's Annual Report on Form 10-K and most recent Quarterly Reports on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
RICHMOND, Calif., Jan 06, 2010 /PRNewswire via COMTEX/ -- Sangamo BioSciences, Inc. announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 2:30 pm PT (5:30 pm ET) on Wednesday, January 13, 2010 at the 28th Annual J.P. Morgan Healthcare Conference which will be held in San Francisco.
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.
SOURCE Sangamo BioSciences, Inc.
Copyright (C) 2010 PR Newswire. All rights reserved
7:03AM Sangamo BioSci announces presentation of preliminary data from Phase 2 study of SB-509 at International ALS Symposium (SGMO) 5.04 : Co announces the presentation of preliminary data from the Phase 2 clinical trial of its ZFP Therapeutic program to develop SB-509 as a treatment for amyotrophic lateral sclerosis at a Work in Progress session at the 20th International Symposium on ALS/MND held in Berlin, Germany. The preliminary data were from the first subjects enrolled in Sangamo's Phase 2 clinical trial, SB-509-801, and demonstrate an approximate doubling of frequency of improved muscle function in subjects with ALS who received two treatments of SB-509 (32%) compared to matched historic controls. In early stage ALS clinical trials, an historic control is frequently used rather than a placebo to maximize the number of subjects receiving the drug.
Sangamo BioSciences Research Collaborators Awarded Grant From California Institute for Regenerative Medicine to Develop Zinc Finger Nuclease-Based Stem Cell Therapy for HIV/AIDS
--$14.5 million award to bring ZFP HIV therapy to the clinic
RICHMOND, Calif, Oct 28, 2009 /PRNewswire-FirstCall via COMTEX/ -- Sangamo BioSciences, Inc. /quotes/comstock/15*!sgmo/quotes/nls/sgmo (SGMO 5.96, -0.19, -3.11%) announced today that the California Institute for Regenerative Medicine (CIRM) has granted a $14.5 million Disease Team Research Award to develop an AIDS-related lymphoma therapy based on the application of its zinc finger nuclease (ZFN) gene-editing technology in stem cells. The four year grant supports an innovative research project conducted by a multidisciplinary team of investigators led by John Zaia, M.D. the Aaron D. and Edith Miller Chair in Gene Therapy and chair of virology, City of Hope. The grant application entitled "Zinc Finger Nuclease-Based Stem Cell Therapy for AIDS" won the highest score of all grants CIRM received in this 1st round of Disease Team Research Award funding.
"Sangamo scientists have developed a ZFN-mediated gene-editing technology that has been demonstrated to make hematopoietic stem cells and mature immune system cells resistant to HIV infection," said Dr. Zaia. "This will be the first test of whether hematopoietic stem cells made HIV resistant using Sangamo's technology can correct the disease. If successful, our work could open the door to ZFN-based cell therapies for other important diseases."
Patients homozygous for a natural mutation (the delta-32 mutation) in the CCR5 gene are resistant to HIV infection by blocking the ability of the virus to enter a cell. Building on this observation, a study published in the New England Journal of Medicine in 2009 reported a potential "cure" in an AIDS patient with leukemia after receiving a bone marrow transplant from a "matched" donor with this delta-32 CCR5 mutation. This approach transferred the hematopoietic stem cells (HSC) residing in the bone marrow from the delta-32 donor, and provided a self-renewable and lifelong source of HIV-resistant immune cells. After transplantation, this patient was able to discontinue all anti-HIV drug treatments, CD4 counts increased, and the viral load dropped to an undetectable level, demonstrating effective transplantation of protection from HIV infection.
This CIRM Disease Team Research Award proposes an approach to modify a patient's own HSC to circumvent the need to find matched donors that carry the delta-32 CCR5 mutation and while providing a renewable and long-lasting source of HIV-resistant cells. Specifically, the grant funds the development of a ZFN approach to treat AIDS patients by first isolating their HSC, modifying them using CCR5-specific ZFNs, and then re-infusing them to reconstitute the immune system with CCR5-negative, HIV-resistant immune cells.
"We are delighted that this research proposal was chosen for funding by CIRM," commented Dr. Philip Gregory, Sangamo's chief scientific officer and vice president, research. "This grant brings together a team of world-renowned experts to develop this novel ZFN-based stem cell therapy for AIDS-related lymphoma through to the clinic. We look forward to working with the team which includes Paula Cannon, Ph.D., associate professor of Molecular Microbiology & Immunology, Keck School of Medicine of the University of Southern California, who has carried out extensive pre-clinical research using our technology in stem cells, and Dr. Zaia and his colleagues at City of Hope who are pioneers in hematopoietic cell transplantation."
"CIRM support for this program is a major validation of our ZFP Therapeutics platform both scientifically and financially and we are very pleased to be part of the exceptional team that received the highest score of all of the grants reviewed by CIRM," said Edward Lanphier, Sangamo's president and CEO.
The CIRM Disease Team Research Awards will fund actively managed multidisciplinary teams engaged in milestone-driven translational research for the development of stem cell-based therapies. The mission of these teams will be to conduct the necessary research and regulatory activities to prepare and file a complete, well supported Investigational New Drug Application (IND) with the Food and Drug Administration (FDA) (and, if desired, other regulatory agencies), to enable Phase I clinical testing.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs and their applications in the treatment of HIV/AIDS, receipt of funds from CIRM, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
http://www.sangamo.com
Sangamo BioSci SGMO Leerink Swann upgraded to Outperform priced target increased from $9 to $11
7:03AM Sangamo BioSci and Sigma-Aldrich announce major expansion of ZFP technology license agreement (SGMO) 7.73 : Co announces a major expansion of their existing license agreement to include the exclusive rights to develop and distribute zinc finger DNA binding protein (ZFP)-modified cell lines for commercial production of protein pharmaceuticals. Additionally, Sigma-Aldrich licensed rights to certain ZFP-engineered transgenic animals for commercial applications. The expanded agreement provides Sigma-Aldrich with exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and ZFP-engineered transgenic animals for livestock, companion animals and therapeutic protein production. Sangamo retained all rights to ZFP-modified transgenic animals for discovery of novel therapeutics and the right to use ZFPs as therapeutic products. Under this agreement, Sigma-Aldrich will make initial payments of $20.0 mln to Sangamo, consisting of an upfront license payment of $15.0 mln and $5.0 mln through the purchase of 636,133 shares of Sangamo common stock at market price. Market price is determined by the average closing price of Sangamo stock over the past 30 trading days, or $7.86 per share. Sangamo is eligible to earn additional contingent commercial license fees of up to $5.0 mln based on certain conditions and thereafter a royalty based upon a percentage of net sales and sublicensing revenue. Sangamo is also eligible to receive commercial milestone payments ranging from $2.0 mln to $10.0 mln, up to a total of $25.0 mln, based upon cumulative product sales.
Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
--Researchers to Receive $486,000 Grant for ZFN-mediated Gene Correction of Sickle Cell Anemia
RICHMOND, Calif., Oct 01, 2009 /PRNewswire-FirstCall via COMTEX/ -- Sangamo BioSciences, Inc. /quotes/comstock/15*!sgmo/quotes/nls/sgmo (SGMO 8.21, -0.33, -3.86%) announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, has been selected to receive a $486,000 Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation. The grant, which will be paid over three years, will support an innovative research project conducted by Dr. Kohn and Sangamo scientists and titled "Beta-globin Gene Correction in Hematopoietic Stem Cells for Sickle Cell Disease."
"ZFN-mediated gene editing is an exciting and now proven technology with the potential to provide a solution for sickle cell anemia and other hemoglobinopathies," said Dr. Kohn. "Despite the fact that sickle-cell anemia was the first genetic disorder for which a molecular cause was identified and one in which every patient has the same gene mutation, the lack of treatment options makes the disease a hugely important problem worldwide. This novel approach will develop the use of efficient ZFN-mediated correction of the sickle mutation in the human beta-globin gene in stem cells from patients with sickle cell disease rather than traditional approaches of gene replacement therapy."
The Doris Duke Innovations in Clinical Research Award (ICRA) provides seed funding for early stage, multi-disciplinary clinical research projects. The 2009 ICRA grants will support a range of approaches to improving the health of patients with sickle cell disease. The research proposed by Dr. Kohn and Sangamo is one of five projects selected to receive grants from the foundation out of a total of 81 applications from 52 teams of investigators for the 2009 ICRA competition.
"We are very pleased that our research proposal was chosen for this prestigious award," commented Dr. Philip Gregory. "Dr. Kohn is a pioneer in the development of hematopoietic stem cell therapies for monogenic diseases and we look forward to continuing our collaboration to develop a novel stem cell therapeutic approach to sickle cell disease."
About Sickle Cell Anemia and Sickle Cell Disease
Sickle cell anemia is a serious disease in which the body makes sickle-shaped red blood cells. This condition is caused by a mutation in the beta-globin gene which leads to the production of abnormal hemoglobin protein. Normal red blood cells are disc-shaped and move easily through blood vessels. Sickle-shaped cells are stiff and sticky and tend to form clumps and get stuck in the blood vessels blocking blood flow to the limbs and organs. Blocked blood vessels can cause pain, serious infections, and organ damage.
Many of the more than 70,000 people living with sickle cell disease in the United States - most of whom are African-American - face a lifetime of painful, debilitating and expensive health problems, with a much-shortened life expectancy. Sickle cell disease takes an even heavier toll in Africa, where approximately 200,000 babies are born with the disease each year. The only FDA-approved drug available for treating sickle cell disease is the anticancer drug hydroxyurea.
About the Doris Duke Charitable Foundation
The mission of the Doris Duke Charitable Foundation is to improve the quality of people's lives through grants supporting the performing arts, environmental conservation, medical research and the prevention of child maltreatment, and through preservation of the cultural and environmental legacy of Doris Duke's properties. Since 1998, the foundation's Medical Research Program has committed approximately $185 million to strengthen and support clinical research, which advances the translation of basic biomedical discoveries into new treatments, preventions and cures for human diseases. To learn more about the program or to receive competition announcements, visit http://www.ddcf.org/mrp.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has two Phase 1 clinical trials to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs and their applications in the treatment of sickle cell disease, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent quarterly report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
http://www.sangamo.com
Recent News
Schering-Plough: VICTOR-E1 study results sustained through 96 weeks (SGP) 28.50 : The co reports long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients. The results showed that vicriviroc plus optimized background therapy achieved durable virologic suppression and increased CD4 cell counts, and was generally well tolerated over two years of therapy. These 96-week results were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)... Seventy patients remained on therapy at the time of the 96-week analysis. The virologic effect seen during the double-blind phase of the study was sustained in these patients during open-label vicriviroc treatment, with the percentage of patients achieving undetectable virus increasing over the course of therapy. Importantly, further improvements in CD4 counts were observed with longer vicriviroc therapy, with a mean increase of 50 cells/mm3 from week 48 of the double-blind study to the end of the 96-week period.
Recent News
Schering-Plough: VICTOR-E1 study results sustained through 96 weeks (SGP) 28.50 : The co reports long-term data with vicriviroc, its investigational CCR5 receptor antagonist, from an ongoing, open-label extension of the Phase II VICTOR-E1 study in treatment-experienced HIV-infected patients. The results showed that vicriviroc plus optimized background therapy achieved durable virologic suppression and increased CD4 cell counts, and was generally well tolerated over two years of therapy. These 96-week results were presented at the 49th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)... Seventy patients remained on therapy at the time of the 96-week analysis. The virologic effect seen during the double-blind phase of the study was sustained in these patients during open-label vicriviroc treatment, with the percentage of patients achieving undetectable virus increasing over the course of therapy. Importantly, further improvements in CD4 counts were observed with longer vicriviroc therapy, with a mean increase of 50 cells/mm3 from week 48 of the double-blind study to the end of the 96-week period.
Sangamo BioSciences Announces Presentation at the JMP Securities Research Conference
RICHMOND, Calif., May 13, 2009 /PRNewswire-FirstCall via COMTEX/ -- Sangamo BioSciences, Inc. announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic(TM) development programs and an overview of the company's business strategy at 10:00 am PT on Wednesday, May 20, 2009 at the Eighth Annual JMP Securities Conference which will be held in San Francisco.
The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
http://www.sangamo.com
Sangamo BioSciences Receives $100,000 Grand Challenges Explorations Grant for Innovative Global Health Research
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7bFF59CC47-E60B-4066-885E-DF706485A422%7d&siteid=nbsh
RICHMOND, Calif., May 4, 2009 /PRNewswire-FirstCall via COMTEX/ -- Sangamo BioSciences, Inc. (SGMO:Sangamo BioSciences Inc
4:00pm 05/04/2009
SGMO, the world leader in the research and development of zinc finger DNA-binding proteins (ZFPs), announced today that it has received a US$100,000 Grand Challenges Explorations grant from the Bill & Melinda Gates Foundation. The grant will support an innovative global health research project conducted by Sangamo scientists and titled "Zinc Finger Nucleases for In Vivo Treatment of HIV Infection."
Sangamo's project is one of 81 grants announced by the Gates Foundation in the second funding round of Grand Challenges Explorations, an initiative to help scientists around the world explore bold and largely unproven ways to improve health in developing countries. The grants were provided to scientists in 17 countries on six continents.
To receive funding, the company showed in a two-page application how its idea falls outside current scientific paradigms and might lead to significant advances in global health. The initiative is highly competitive, receiving more than 3,000 proposals in this round.
People born with a genetic mutation in their CCR5 gene, a critical receptor for HIV entry, are naturally resistant to HIV infection. Sangamo has designed and engineered zinc finger DNA-binding protein nucleases (ZFN(TM)) that specifically disrupt the CCR5 gene in cells. In preclinical work published with their collaborators at the University of Pennsylvania, Sangamo researchers demonstrated that in an animal model of HIV infection ZFN-modified human immune cells survived and multiplied preferentially, leading to an increase in CD4+ T-cell counts and a reduction in viral load suggesting resistance to HIV (Nat Biotechnol. 2008 Jul; 26(7):808-16). A Phase 1 clinical trial is ongoing at the University of Pennsylvania to evaluate the safety and tolerability of SB-728-T, a ZFP Therapeutic based on Sangamo's CCR5-disrupting ZFNs. SB-728-T is being tested as an ex-vivo, or cell-therapy, approach for the treatment of HIV/AIDS.
Sangamo proposes to develop the next generation of this therapeutic approach, an in-vivo, or direct injection protocol. The resulting CCR5-negative cells will be protected from HIV infection and have the potential to provide long term control of the opportunistic infections characteristic of AIDS as well as HIV itself. Ultimately this approach could be combined with traditional vaccination strategies to further arm the immune system against HIV infection.
"We are very pleased that our research proposal was chosen for this prestigious award," commented Edward Lanphier, Sangamo's president and CEO. "We already have an ongoing Phase 1 clinical trial to evaluate our ZFN-based approach as an ex-vivo formulation. This grant will aid our efforts to develop the next generation of this ZFP Therapeutic, an in-vivo formulation for direct injection that could make our approach accessible to HIV-infected patients throughout the world."
"The winners of these grants are doing truly exciting and innovative work," said Dr. Tachi Yamada, president of the Gates Foundation's Global Health Program. "I'm optimistic that some of these exploratory projects will lead to life-saving breakthroughs for people in the world's poorest countries."
About Grand Challenges Explorations
Grand Challenges Explorations is a five-year, $100 million initiative of the Gates Foundation to promote innovation in global health. The program uses an agile, streamlined grant process - applications are limited to two pages, and preliminary data are not required. Proposals are reviewed and selected by a committee of foundation staff and external experts, and grant decisions are made within approximately three months of the close of the funding round.
Applications for the next round of Grand Challenges Explorations are being accepted through May 28, 2009. Grant application instructions, including the list of topic areas in which proposals are currently being accepted, are available at the Grand Challenges Explorations website.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, human, plant and research applications of Sangamo's ZFP technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
http://www.sangamo.com
Copyright (C) 2009 PR Newswire. All rights reserved
Sangamo BioSciences Announces Publication in Nature of the Use of Zinc Finger Nucleases to Accelerate Precision Trait Stacking in Commercial Crop Species
http://www.marketwatch.com/News/Story/Story.aspx?guid=%7b1B8A6BC1-2776-49AB-9B65-F9DFCA79DBCA%7d&siteid=nbsh
Last update: 1:05 p.m. EDT April 29, 2009
RICHMOND, Calif., April 29, 2009 /PRNewswire-FirstCall via COMTEX/ -- Sangamo BioSciences, Inc. (SGMO:Sangamo BioSciences Inc
News , chart , profile , more
Last: 4.57+0.20+4.58%
1:08pm 04/29/2009
4.6%) announced today continued success of its zinc finger DNA-binding protein (ZFP) technology. New research published in the scientific journal Nature by licensing partner Dow AgroSciences and Sangamo demonstrated the successful application of ZFP technology for the efficient generation of maize plants with multiple, commercially important traits. The techniques described are broadly applicable across plant species and traits and establish a new method for rapid and precise crop development.
In the study published in the Advance Online edition of Nature, scientists at Dow AgroSciences and Sangamo used ZFP Nucleases (ZFNs(TM)) to introduce a herbicide tolerance gene into a pre-determined address in the maize genome, simultaneously eliminating the expression of an enzyme involved in the production of phytate, a natural but undesirable compound found in feed crops and a cause of environmental pollution. In a rapid, single step process the gene involved in phytate production was disabled and permanently linked with the acquisition of herbicide tolerance - i.e. stacking the two desired characteristics in the plant and generating reduced phytate, herbicide tolerant corn.
"These data reinforce that EXZACT(TM) Precision Technology has the potential to redefine the future of agriculture driving productivity gains globally and greatly enhancing sustainability in major food crops such as maize," said Jerome Peribere, president and CEO of Dow AgroSciences. "This technology provides flexibility and versatility in plant biotechnology research enabling developers, such as Dow AgroSciences and our collaborators, to enhance the discovery and development of novel traits for the crop production industry."
"The future of crop improvement lies in the ability to identify and efficiently stack multiple, commercially valuable traits at predetermined sites in the plant genome with absolute precision. With this technology, we are taking the process of genome modification and trait development to a new level of sophistication," said Vipula Shukla, project leader at Dow AgroSciences. "We have demonstrated that EXZACT Precision Technology enables us to rapidly develop new trait combinations in economically important crops, including commodity crops, vegetables, ornamentals, trees and biomass crops. The speed and precision of this approach, which will replace the random and laborious approaches currently employed, can result in significant reduction in the time and effort required to commercialize enhanced crops."
"These data are a powerful demonstration of the broad applicability of our ZFP technology platform," stated Philip Gregory, D. Phil., Sangamo's vice president of research. "Furthermore this is not simply a demonstration of 'cool science' in a model system but a real-life application of the technology to provide a commercially relevant solution to a problem. Our ZFN gene editing technology is being used to precisely and specifically disrupt, correct or add genes to create novel cell lines and whole organisms - both plant and animal. Today, ZFPs are being used to generate improved crops, powerful research reagents and novel drugs for the treatment of intractable human diseases."
In June 2008 Dow AgroSciences exercised its option to become the exclusive licensee and sublicensor of Sangamo's proprietary ZFP technology for the development of products in plants and plant cell cultures following a successful research collaboration that began in October 2005.
"It has been very rewarding to witness the rapid translation of our technology into commercially relevant crop products," said Edward Lanphier, Sangamo's president and chief executive officer. "The Dow AgroSciences team has done an outstanding job of exploiting the powerful science of our ZFP platform."
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy and ALS. Sangamo also has a Phase 1 clinical trial to evaluate safety and clinical effect of a ZFP Therapeutic for the treatment of HIV/AIDS. Other therapeutic development programs are focused on cancer, neuropathic pain, nerve regeneration, Parkinson's disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for gene modification. Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences, Sigma-Aldrich Corporation and several companies applying its ZFP technology to engineer cell lines for the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, human, plant and research applications of Sangamo's ZFP technology platform, strategic partnerships with collaborators and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent report on Form 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
EXZACT(TM) Precision Technology is a trademark of Dow AgroSciences LLC.
ZFP Therapeutic(TM), ZFP TF(TM) and ZFN(TM) are trademarks of Sangamo BioSciences, Inc.
SOURCE Sangamo BioSciences, Inc.
http://www.sangamo.com
Post from Investorvillage.com
Re: Just out-JMP Sec-"Expect more visibility+presentation by DowAgra @ Dec 5 analyst day next wk.2008 will be "transformational". Reiterate Strong Buy and $30 target price."
Rob_Cos,
Thanks for another highly informative post. I liked the "In particular, we are interested in the revenue potential from the DowAgra collaboration, under which terms and commercial potential remain challenging to value" part immensely since I have gone through various exercises to do that very thing. My basic assumption (please take this with a grain of salt, tequila/lime optional) is that someone will pay a royalty of 3.3% to genetically engineer (using ZFP's of course) a high output stain of algae which based on $3.00/gallon fuel equals $0.10/gallon. Now what kind of biofuel production is possible or being planned?
"PetroSun BioFuels intends to establish one thousand algae cultivation
pods to produce algal oil as feedstock for biofuel refineries within
three years. A single cultivation pod could produce over 2.5 Million
gallons a year based on lower case production projections.
Accomplishing this milestone would give the company the capacity to
produce approximately 2.56 Billion gallons of algal oil each year. "
I have done limited DD on PetroSun, PSUD.pk, know they have an efficient method of separating the oil using an ultrasonic technique from Bioco. Anyway, taking the 2.56 B gallons x $0.10/gal. produces a healthy $256,000,000 annually from just one biofuel producer.
This is really one step above a WAG but thought members of the board might enjoy a little humor this evening. I hope Dec. 5th adds color and clarity.
Rayn
16 Reasons to own Sangamo:
A game changing technology with a host of applications in medicine and biotechnology, including gene therapy, stem cell modification, protein production and plant breeding.
Savvy business management with deals and alliances that include DOW, Sigma Aldrich and Genentech.
A rapidly developing pipeline that includes angiogenesis, neural regeneration and an entirely novel approach to cure AIDS
Sound science published in top journals and a scientific advisory board that includes a Nobel laureate.
Targeting DNA ‘provokes biological outcomes not achievable at the RNA or protein level’ – offering an entirely new way to treat disease.
They control the intellectual property rights.
They acquired their sole competitor.
Medical breakthroughs will come from combining ZFP technology with stem cells and gene therapy
Promising results for SB509 can be applied in multiple indications (including DN, PAD, ALS and SCI).
The market for DN alone is in excess of $1 billion per annum.
The market for a pain repressor is $750 per annum
New product candidates can be developed in weeks.
Recent results in stem cells promise widespread dissemination of the technology and royalties from Sigma Aldrich.
Sigma Aldrich royalties could exceed $100 million per annum.
Agricultural biotechnology is poised for explosive development
DOW milestones are being met ahead of time, with a deal in the making.
Recs: 18 Just out-JMP Sec-"Expect more visibility+presentation by DowAgra @ Dec 5 analyst day next wk.2008 will be "transformational". Reiterate Strong Buy and $30 target price."
JMP SECURITIES
Biotechnology – Update
November 29, 2007
Sangamo BioSciences, Inc. (1)
STRONG BUY
Target Price $30.00
Expect Eventful Year in 2008 and More Visibility on DowAgra Collaboration
INVESTMENT HIGHLIGHTS
· Expect 2008 to be an eventful year for Sangamo with more visibility on the DowAgra collaboration at upcoming Analyst Day; reiterate Strong Buy rating and $30 price target. We sat down with Sangamo management on Tuesday night and had a chance to discuss upcoming clinical and corporate milestones. From our conversation, we anticipate 2008 could be a transformational year for the company. Specifically, we look forward to data and progress in multiple clinical programs that could broaden the market potential of lead zinc-finger protein (ZFP) therapeutic, SB-509. We believe these Phase II data could encourage would-be corporate collaborators to engage in a significant “bio-buck” drug development or technology access partnership. We anticipate results from the Phase II trials in mild to moderate diabetic neuropathy (DN) and severe DN with nerve block in 2H08 and initiations of Phase II SB-509 trials in stem cell mobilization (1Q08) and amyotrophic lateral sclerosis (ALS, 1H08), Phase I trial of IL-13 zetakine in glioblastoma (1H08), and Phase I trial of ZFN-CCR5 in HIV (2H08). We also anticipate the company to end FY08 with over $50 million in cash and equivalents, positioning Sangamo well to negotiate a drug development collaboration post-Phase II data. Our cash estimates do not assume any milestone payments from the company’s current collaborations with DowAgra Sciences, Sigma Aldrich, or Genentech (DNA, not rated), which could provide additional upside to the company’s balance sheet. In particular, we are interested in the revenue potential from the DowAgra collaboration, under which terms and commercial potential remain challenging to value. However, at Sangamo’s Analyst Day on December 5, we could see a presentation being given by a DowAgra representative who may shed light on projects under the agreement and provide concrete bases to value potential revenues to Sangamo from milestones payments and licensing rights. Our $30 price target is based on a NPV analysis of US SB-509 revenue potential.
INVESTMENT RISKS
Given Sangamo is still in the development stage, the primary risk to our investment thesis involves the ability of it to progress its development programs into later stage trials. In addition and in relation to its internal research programs, other risks to our investment thesis involve being able to successfully progress these programs into clinical trials and subsequently into later stage trials. The last risk we would point out is the company's ability to continue to fund operations through product commercialization.
COMPANY DESCRIPTION
Richmond, California-based Sangamo BioSciences, Inc. uses its proprietary zinc finger DNA-binding protein (ZFP) technology to develop gene therapy treatments for a number of diseases. The company's lead therapeutic, SB-509, is a ZFP that activates the VEGF-A gene in order to promote blood vessel growth, nerve regeneration, and neuroprotection. Sangamo has multiple clinical and preclinical programs with SB-509 in several vascular and neurodegenerative diseases, including diabetic neuropathy, peripheral arterial disease, critical leg ischemia, amyotrophic lateral sclerosis, and spinal cord injury. Diabetic neuropathy is the leading indication in Phase II development. Other early stage programs include ZFN CCR5 for the treatment of HIV and IL-13 zetakine for glioblastoma.
FIGURE 1: Sangamo Biosciences, Inc. Earnings Model ($000s except per share data)
FY06A Mar-07A Jun-07A Sep-07A Dec-07E FY07E FY08E FY09E FY10E
Federal government grants - - - -
Collaboration revenue 7,885 1,422 2,584 2,325 3,150 9,481 14,093 18,502 23,352
Partnered therapeutic royalties 5,000 11,000 15,000
Proprietary therapeutic revenue 25,000 52,000
Total revenue 7,885 1,422 2,584 2,325 3,150 9,481 19,093 54,502 90,352
R&D 21,527 5,430 6,309 5,916 6,330 23,985 26,863 29,550 31,027
SG&A 7,087 1,999 2,113 1,728 1,971 7,811 8,280 5,374 5,911
Restructuring charge
Impairment of patents and goodwill
Stock-based compensation - - - -
Total operating expense 28,614 7,429 8,422 7,644 8,301 31,796 35,143 34,924 36,939
Total operating expense excluding one-time and non-cash charges 28,614 7,429 8,422 7,644 8,301 31,796 35,143 34,924 36,939
Operating income (loss) (20,729) (6,007) (5,838) (5,319) (5,151) (22,315) (16,050) 19,578 53,414
Operating income (loss) excluding one-time and non-cash charges (20,729) (6,007) (5,838) (5,319) (5,151) (22,315) (16,050) 19,578 53,414
Interest income (expense) 2,411 648 657 1,051 798 3,154 709 932 1,385
Other income 454
Net income (loss) (17,864) (5,359) (5,181) (4,268) (4,353) (19,161) (15,341) 20,306 41,099
Net income (loss) excluding one-time and non-cash charges (17,864) (5,359) (5,181) (4,268) (4,353) (19,161) (15,341) 20,306 41,099
EPS (0.55) (0.15) (0.15) (0.11) (0.11) (0.52) (0.41) 0.54 1.10
EPS excluding one-time and non-cash charges (0.55) (0.15) (0.15) (0.11) (0.11) (0.52) (0.41) 0.54 1.10
Ave. shares outstanding 32,502 35,057 35,136 38,925 38,964 37,020 37,132 37,317 37,504
Source: Company filings and JMP Securities estimates
Sangamo BioSciences Reports Second Quarter 2007 Financial Results
http://www.therapeuticsdaily.com/news/article.cfm?contenttype=sentryarticle&contentvalue=1437926....
PR Newswire Europe (inc. UK Disclose) - Jul. 24, 2007
RICHMOND, Calif., July 24 /PRNewswire-FirstCall/
Sangamo BioSciences, Inc. today reported financial results for the quarter ended June 30, 2007. Revenues for the second quarter of 2007 were $2.6 million as compared to second quarter 2006 revenues of $1.8 million. Second quarter 2007 revenues were from Sangamo's partnerships in the areas of plant agriculture, private foundation and federal government research grants and enabling technologies.
The consolidated net loss for the quarter ended June 30, 2007 was $5.2 million, or $0.15 per share, as compared to a net loss of $3.3 million, or $0.11 per share, in the same period of 2006. At June 30, 2007, the company had cash, cash equivalents, investments and interest receivable of $44.6 million.
Total second quarter 2007 operating expenses were $8.4 million as compared to $5.8 million in the prior year period. Research and development expenses were $6.3 million for the three months ended June 30, 2007 as compared to $4.0 million for the second quarter of 2006. The increase in research and development expenses for the second quarter of 2007 compared with the same period in 2006 is principally due to increased expenses associated with our clinical program in diabetic neuropathy and pre-IND programs to develop ZFP Therapeutics for the treatment of HIV/AIDS and for glioblastoma. General and administrative expenses were $2.1 million for the second quarter of 2007 as compared to $1.8 million for the same period in 2006.
Net interest and other income for the second quarter of 2007 was $657,000 as compared to $745,000 in the comparable period of 2006.
Recent Highlights
-- Sangamo raised $30 million in a registered direct offering to
institutional investors. On July 17, Sangamo announced that it had sold an aggregate of 3,278,689 shares of common stock, at a price of $9.15 per share, for gross proceeds of approximately $30.0 million, before fees and expenses. -- Sangamo and Sigma-Aldrich Corporation established a major alliance to develop and commercialize high value laboratory research reagents based
upon zinc finger DNA-binding protein (ZFP) technology. Pursuant to the agreement announced on July 10, Sangamo received an upfront payment of $13.5 million which included license fees and sale of one million shares of Sangamo stock. Sangamo is also eligible to receive development and commercial milestone payments and royalties on product sales. -- Positive data from the Phase 1b clinical trial of ZFP Therapeutic(TM), SB-509, for diabetic neuropathy presented at the American Diabetes Association Meeting. Clinical investigator, Mark Kipnes, M.D.,
presented data from this study that demonstrate statistically
significant improvements in nerve conduction velocity and quantitative sensory testing in subjects with mild to moderate diabetic neuropathy over a six month period after a single administration of SB-509. -- Sangamo received unanimous approval from the National Institutes of Health Recombinant DNA Advisory Committee (RAC) for two ZFN Therapeutic programs. Two ZFP nuclease (ZFN) pre-IND therapeutic programs --
modification of the CCR5 gene in human primary T-cells for the
treatment of HIV/AIDS and a novel therapy for the treatment of
glioblastoma -- were reviewed and unanimously approved by the RAC on June 19. -- Continued progress in achievement of milestones in collaboration with Dow AgroSciences. Sangamo and Dow AgroSciences jointly announced the successful achievement of research milestones as part of our joint Research and Commercial License Agreement. The milestones represent the successful application of Sangamo's ZFP technology for the generation of specific traits in two major crop species -- maize and canola. -- Sangamo entered into a Research and License Agreement with Genentech in the area of protein pharmaceutical production. Under the agreement announced on April 30, Sangamo will develop ZFNs(TM) designed to make targeted modifications to the genome of Genentech cell lines for use in mammalian cell-based protein pharmaceutical production. Genentech has paid Sangamo an upfront fee, and will pay an ongoing technology access fee and certain payments upon achievement of specified milestones relating to the research of ZFNs and the development and commercialization of products manufactured using a modified cell line created by ZFN technology. -- Initiation of Phase 2 clinical trial of SB-509 in subjects with moderate to severe diabetic neuropathy (DN) or "blocked nerves".
Sangamo announced the initiation of a second Phase 2 clinical trial; a randomized, single-blind, placebo-controlled, repeat-dosing study designed to evaluate the clinical safety and clinical effects of repeat administration of SB-509 in diabetic subjects that have "blocked nerves," or unmeasurable nerve conduction velocity (NCV), in at least one of the nerves in the leg.
Six-Month Results
For the six-month period ended June 30, 2007 the consolidated net loss was $10.5 million, or $0.30 per share, compared with a consolidated net loss of $6.1 million, or $0.20 per share, in the comparable period in 2006. Revenues for the first six months of 2007 were $4.0 million as compared to $3.9 million in the same period of 2006. Total operating expenses for the six months ended June 30, 2007 and 2006 were $15.9 million and $11.2 million, respectively.
Conference Call and Webcast
Sangamo will host a conference call today at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.
The conference call dial-in numbers are 888-802-2278 for domestic callers and 913-312-1264 for international callers. The passcode for the call is 1436008. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investor section http://investor.sangamo.com/index.cfm under "Events and Presentations". For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8.00 p.m. ET on July 24, 2007 to July 31, 2007. The conference call replay numbers for domestic and international callers are 888-203-1112 and 719-457-0820, respectively. The conference ID number for the replay is 1436008. The webcast will be available on the Sangamo website for two weeks after the call.
About Sangamo BioSciences, Inc.
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effects in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Research at Sangamo is partially funded by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology (NIST). Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com/.
Sangamo at Drug Discovery & Development of Innovative Therapeutics Conference - 8/8/07
Wednesday, August 8, 2007
8:25
Chairperson's Opening Remarks
Elena Sebokova, Ph.D., Disease Area Head, Metabolic Disease, F. Hoffmann-La Roche Ltd
Case Studies: Moving a Compound from Discovery to Preclinical to Clinical Proof-of-Concept
10:15
SB-509 : A ZFP Therapeutic(TM) in Phase II Trials for the Potential Treatment of Diabetic Neuropathy
Engineered zinc-finger proteins (ZFP) extend our therapeutic arsenal by addressing disease at the DNA level. SB-509 is an investigational ZFP Therapeutic(TM) targeting the potent angiogenic neuro-protective and neuro-regenerative factor VEGF-A. The ZFP platform and phase I studies of SB-509 (now in Phase II) revealing anecdotal evidence of efficacy will be presented.
Philip D. Gregory, D.Phil., Vice President of Research, Sangamo Bioscienes Inc.
Sangamo (SGMO) to sell 3,278,689 shrs @ $9.15 per shr
http://biz.yahoo.com/bizj/070717/1492201.html?.v=1
...proceeds of $30 million before fees and expenses....
...JMP Securities and Piper Jaffray & Co. are acting as joint lead placement agents...
...Leerink Swann & Co. and Janney Montgomery Scott are acting as co-placement agents....
...The deal is expected to close July 20,...
...Sangamo announced on July 10 that it had signed a $13.75 million deal with Sigma-Aldrich Corp. of St. Louis to develop its zinc finger DNA-binding protein technology into products useful in research labs....
See message #1
Listen to lastest conferance call
They are the only ones that do what they do..
ISIS has many with them same intelectual property, SGMO has none.
Can you elaborate on that ..
....would be interesting to know what DD you dug up, if you don't mind?
ISIS has a lot of upside, but I think SGMO has a better, and more exclusive platform.
But look at the patent list of ISIS. Wouldn't that be a better play?
I am surprised at the general lack of interest in this stock. Out of all the biotech stocks I own, I feel this one has the greatest potential. Would hate to see ( well I wont allow it ) to become like the Yahoo messeage board but would like to see more view points.
Sangamo BioSciences (SGMO) & Sigma-Aldrich (SIAL) Announce Alliance
..."to Develop Zinc Finger-Based Laboratory Research Reagents --- Companies Combine Proprietary Technologies to Create High Value Research Products"... , Tuesday July 10, 4:00 pm ET
http://biz.yahoo.com/prnews/070710/aqtu068.html?.v=16
Article related quotes:
http://finance.yahoo.com/q/cq?s=SGMO,SIAL&d=v6
Monday July 9...During the quarter Genentech formed a collaboration with Sangamo BioSciences Inc. over technology that regulates how genes work within a cell....
http://biz.yahoo.com/ap/070709/earnings_preview_genentech.html?.v=1
SGMO Added to NASDAQ Biotechnology Index
http://www.pr-inside.com/sangamo-biosciences-added-to-nasdaq-biotechnology-r129440.htm
May 21, 2007: ...Sangamo BioSciences, Inc. , in the development and commercialization of zinc finger DNA-binding proteins (ZFPs) as novel therapeutics, was added to the NASDAQ Biotechnology Index(R)...
The NASDAQ Biotechnology Index
...includes securities of Nasdaq-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals which also meet other eligibility criteria. The NASDAQ Biotechnology Index is calculated under a modified capitalization-weighted methodology. ...
http://dynamic.nasdaq.com/dynamic/nasdaqbiotech_activity.stm
At the bottom is a table of the components:
Click on the security's symbol for a Full Quote.
iShares Nasdaq Biotechnology IBB
http://www.nasdaq.com/aspxcontent/etfprofile.aspx?Ticker=IBB
Specialty-Health ETFs:
http://finance.yahoo.com/etf/browser/mkt?c=etf_sh&k=5&f=0&o=d&cs=1&ce=39
Sangamo BioSciences Announces Presentation of ZFP Therapeutic Data From Nerve Regeneration Program at American Society for Neural Therapy and Repair Meeting
Thursday May 3, 4:05 pm ET
Statistically Significant Improvements in Function in Spinal Cord Injury Model With ZFP TF Treatment
RICHMOND, Calif., May 3 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today the presentation of preclinical data from its ZFP Therapeutic(TM) program in nerve regeneration at the Fourteenth Annual Conference of the American Society for Neural Therapy and Repair. The data generated, in a model of spinal cord injury (SCI), demonstrate that treatment of the spinal cord at the time of injury with a VEGF ZFP TF had a statistically significant effect on recovery of hind-limb function as well as a number of other measures of nerve integrity and health.
The work was carried out in the laboratory of Dr. Michael Fehlings who holds the Krembil Chair in Neural Repair and Regeneration at the Krembil Neuroscience Center, Toronto Western Hospital and the Division of Neurosurgery, Faculty of Medicine, University of Toronto, Ontario, Canada. Dr. Fehlings is a Christopher Reeve Foundation Scientific Advisory Council member and a leading expert in the molecular mechanisms and treatment of SCI.
In collaboration with Dr. Fehlings and his colleagues, Sangamo is evaluating a zinc finger DNA-binding protein transcription factor (ZFP TF(TM)), designed to upregulate the expression of the gene encoding vascular endothelial growth factor (VEGF-A) in spinal cord injury (SCI) models. In addition to its effects on angiogenesis or blood vessel growth, VEGF-A has been demonstrated to have direct neurotrophic and neuroprotective properties in several models that assess nerve integrity and health. In addition, Sangamo is currently developing SB-509, a plasmid formulation of this same ZFP TF, for the treatment of diabetic neuropathy and has two ongoing Phase 2 trials in this area.
Dr. Fehlings and his colleagues observed that administration of the ZFP TF into the spinal cord at the time of injury produced measurable VEGF ZFP TF and increased levels of all of the major isoforms of the VEGF protein. They observed a corresponding neuroprotective effect with a statistically significant decrease in nerve fiber degradation and post-injury nerve cell death. They also noted an increase in blood vessel density around the injury. Most importantly, in a severe model of SCI where animals are paraplegic post- injury, they observed a statistically significant (p<0.0001) improvement of hind-limb function over time.
"I am very impressed by the improvements that we were able to generate through treatment of acutely injured spinal cord with the VEGF ZFP TF," stated Dr. Fehlings. "In earlier studies we had observed clear increases in VEGF protein levels and good evidence of a neuroprotective effect of the ZFP TF. In these more recent experiments we have seen evidence of improved functional outcomes that are quite impressive compared with any other therapeutic approach that we have evaluated including stem cell therapies. We look forward to continuing these studies in collaboration with Sangamo and believe that this VEGF-activating ZFP TF may hold promise as a unique therapy for spinal cord injury and other forms of neural injury."
"Dr. Fehling's studies, particularly the experiments that demonstrate an improvement in hind-limb function, are very encouraging," said Dale Ando, M.D. Sangamo's vice president of therapeutic development and chief medical officer. "The outcomes of these studies are consistent with other data from a variety of models that suggest that our ZFP TF activator of VEGF expression has regenerative effects on nerves and a positive effect on the health of nerves injured by both mechanical means such as in spinal cord injury and the toxicity that is a function of diabetes. We are very pleased to continue to work with Dr Fehlings who is world-renown for his work on SCI and has significant clinical trial experience in this area."
S. Kaye Spratt, Ph.D., Director, Preclinical Development at Sangamo BioSciences, Inc., will chair a session on novel therapies at the meeting.
About Spinal Cord Injury
Spinal Cord Injury (SCI) is damage to the spinal cord that results in a loss of function such as mobility or feeling. The National Spinal Cord Injury Statistical Center (NSCISC) estimates that there are approximately 11,000 new cases each year primarily in young adults. The spinal cord is the major bundle of nerves that carries nerve impulses to and from the brain to the rest of the body. The spinal cord does not have to be severed in order for a loss of function to occur. In fact, in most people with SCI, the spinal cord is intact, but the damage to it results in loss of function.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development program is currently in Phase 2 clinical trials for evaluation of safety and clinical effect in patients with diabetic neuropathy. Phase 1 clinical trials are ongoing to evaluate a ZFP Therapeutic for peripheral artery disease. Other therapeutic development programs are focused on cancer and HIV/AIDS, neuropathic pain, nerve regeneration, ischemic heart disease and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as X-linked SCID and hemophilia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. For more information about Sangamo, visit the company's web site at http://www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs as ZFP Therapeutics, applications of Sangamo's ZFP TF technology platform and clinical trials of ZFP Therapeutics. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, uncertainties relating to the initiation and completion of stages of ZFP Therapeutic clinical trials, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo BioSciences, Inc. assumes no obligation to update the forward-looking information contained in this press release.
Source: Sangamo BioSciences, Inc.
SGMO by Jerome Peribere of Dow AgroSciences
February 13, 2007: Jerome Peribere, President and CEO of Dow AgroSciences, presentation includes information on Sangamo Biosciences, Inc. (SGMO) at the Goldman Sachs Agricultural Chemicals Conference
http://media.corporate-ir.net/media_files/irol/80/80099/dow_070213.pdf
Nov 2006: Dow AgroSciences LLC, a wholly owned subsidiary of The Dow Chemical Company, and Sangamo BioSciences, Inc. announced the successful completion of multiple research milestones as part of their Research and Commercial License Agreement initiated October 2005.
http://www.seedquest.com/News/releases/2006/november/17559.htm
Includes:
The three-year agreement provides Dow AgroSciences with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology for the development of products in plants and plant cell cultures.
Oct 2005 : Dow AgroSciences LLC and Sangamo BioSciences, Inc.
http://www.bionity.com/news/e/49419/
announced the signing of a Research and Commercial License Agreement. The agreement provides Dow AgroSciences with access to Sangamo's proprietary zinc finger DNA-binding protein (ZFP) technology for use in plants and plant cell cultures to develop products in areas including, on an exclusive basis, plant agriculture and industrial products, and, on a non-exclusive basis, animal health and biopharmaceutical products produced in plants.
**********************************************************************************
Dow AgroSciences
http://www.dowagro.com/homepage/index.htm
Sangamo Biosciences, Inc.
http://www.sangamo.com/index.php
******************************************************************************
Collaborations also with Rosetta Inpharmatics, Inc. :
Functional genomic studies on potential therapeutic targets
http://www.biospace.com/company_profile.aspx?CompanyId=3896
Weekly Gainers List includes SGMO +25.47%
Stocks over $5 posting the largest percentage gain over the last five sessions include:
http://finance.yahoo.com/marketupdate/inplay
SILC +50.5%, MDCC +47.4%, CPRX +45.56%, FRC +40.83%, NYMX +38.56%, XIDE +38.52%, REFR +37.19%, MCDTA +34.28%, LEV +31%, SGEN +30.92%, SCUR +29.82%, WEBX +29.64%, SYGR +28.79%, ROCM +26.84%, CRR +26.64%, SNCI +25.54%, SGMO +25.47%, BRLC +25.12%, BOW +24.55, CHRW +23.35%, ISRG +22.23%, FBP +22.03%, CUTR +22.31%, SIRF +21.81%, CNQR +21.68%, OPNT +21.23%, IDP +21.13%, TLGD +20.55%, POP +20.53%, SIGM +20.46%, ODFL +20.39%, RTIX +20.38%,
Information below collected from postings on various website message boards and C/W's free content re Bulls&Bears Wrap-up.
Two recent C/W recommendations:
SGMO +25.47% and SIGM +20.46%
5 day chart:
http://finance.yahoo.com/q/bc?s=SGMO&t=5d&l=on&z=l&q=l&c=SIGM
02/01/07 C/W Stk Alert: Sangamo Biosciences (SGMO)
-- Buy under $8.50, strong Buy under $7.50, accumulate under $9.50; target is $22
01/29/07 C/W Stk Alert: Sigma Designs (SIGM)
-- Buy under $25, strong buy under $23, accumulate under $27; target $45 by 2008
On 01/13/07: He picked SIGM for Fox Bulls And Bears Stock X-Change
http://www.changewave.com/freecontent/viewwrapup.html?source=/freecontent/tobysfiles/2007/01/bullsan...
SGMO recommended by Toby Smith in his newsletter
To read the posts by rob_cos go to Yahoo's SGMO board:
Part 1
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_S/threadview?m=tm&bn=16434&tid=...
Part 2
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_S/threadview?m=tm&bn=16434&tid=...
Part 3
http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_S/threadview?m=tm&bn=16434&tid=...
NOTE: I am not quoting the recommendation, due to copyright protection, etc, but the it appears most of the T.S. buy info was posted by rob_cos.
Sangamo BioSciences Provides Update on Company's Accomplishments in 2006 and Objectives for Next 12 Months
Thursday December 7, 7:00 am ET
CEO Edward Lanphier Views 2007 as 'Transformational Year' With Maturing Pipeline, Preeminent IP Position, and Opportunities for Additional Collaborative Partners
RICHMOND, Calif., Dec. 7 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO - News) announced today that the company provided an update on its achieved milestones in 2006 and previewed objectives for 2007 during its annual Investor and Analyst Briefing held in New York this week.
"We are excited about the level of accomplishment in 2006, having successfully achieved major goals, including the initiation of our first Phase 2 clinical trial, advancement and consolidation of our clinical pipeline with the acquisition of all ZFP Therapeutic(TM) angiogenesis assets, progress in our research collaboration with Dow AgroSciences and success in continuing to monetize our technology outside the therapeutic space in multiple cell engineering collaborations," said Edward Lanphier, president and CEO of Sangamo BioSciences. "These accomplishments are testimony to the quality of our research and development teams and collaborators and the power of our technology platform."
Mr. Lanphier continued, "I believe that the progress that we have made in 2006 places us in a strong position to advance our business strategy and clinical programs in 2007. By the second half of 2007, we expect to have two ongoing Phase 2 trials in patients with diabetic neuropathy and to be in a position to initiate two Phase 1 trials in patients with HIV infection and glioblastoma. These objectives, as well as additional progress in our collaboration with Dow AgroSciences, will be key to further enhancing a market-leading presence for our technology. As has become increasingly evident, an innovation gap is looming in the pharmaceutical sector, and we believe that our progress in advancing our technology platform, which is unique in its generation of novel highly differentiated therapies and products, will create interest among potential partners for our programs."
Sangamo Accomplishments in 2006
During the briefing several of the company's achievements were highlighted including:
* The initiation of Sangamo's first Phase 2 clinical trial. A
repeat-dosing, double blind, multi-endpoint trial was initiated for
SB-509, a formulation of a zinc finger DNA-binding protein transcription
factor (ZFP TF(TM)) activator of vascular endothelial growth factor
(VEGF), in patients with mild to moderate diabetic neuropathy (DN). The
study was initiated following encouraging Phase 1 results that showed
that the drug was well tolerated at doses that had been shown to be
efficacious in animal models and anecdotal improvement of clinical
symptoms in patients with DN. Funding of up to $3M from the Juvenile
Diabetes Research Foundation will support broad clinical efficacy tests
in the Phase 2 trial.
* The acquisition of Edwards Lifesciences' ZFP angiogenesis platform
including two clinical programs, a completed Phase 1 study in patients
with critical limb ischemia (CLI) and an ongoing Phase 1 trial in
intermittent claudication. Sangamo also gained rights to a mature
preclinical program targeting ischemic heart disease, as well as
potential applications in neurovascular disease, which encompasses a
broad range of indications including stroke and spinal cord injury.
* Achievement of the first milestones in Sangamo's research collaboration
with Dow AgroSciences to develop its ZFP technology to enable the
efficient and reproducible generation of combinations or stacks of
multiple new traits in plants.
* Sangamo also estimated that it would end 2006 with approximately $53M in
cash and cash equivalents, ahead of previous guidance.
Select 2007 Objectives
During the briefing Sangamo also discussed the following objectives for 2007:
* By the second half of 2007, Sangamo expects to complete accrual for its
repeat-dosing Phase 2 trial of SB-509 in patients with mild to moderate
DN, and anticipates initiating and completing accrual for a second
Phase 2 trial of the same drug in patients with "blocked nerve"
conduction. This second Phase 2 trial, which was unveiled at the
briefing, is being initiated based on clinical observations from the
Phase 1 study of SB-509 in which improvements in nerve conduction
velocity (NCV) were observed in patients with advanced nerve block.
These and other data from the Phase 1 DN program will be presented in
2007 at appropriate medical and scientific conferences.
* Sangamo also plans to initiate a Phase 1 trial of a ZFP Therapeutic to
treat HIV infection in the second half of 2007. The company most
recently reported findings from its program to develop a zinc finger
DNA-binding protein nuclease (ZFN) for the treatment of HIV/AIDS at the
46th Annual Interscience Conference on Antimicrobial Agents and
Chemotherapy. The data demonstrated that administration of Sangamo's
CCR5-ZFNs enabled the generation of a population of CCR5-modified,
T-cells that were permanently resistant to HIV. The company expects to
file an IND and initiate clinical testing with collaborator Dr. Carl
June, Director of Translational Research at the Abramson Family Cancer
Research Institute at the University of Pennsylvania School of Medicine.
* Sangamo also discussed for the first time a collaboration to develop
ZFNs that can disrupt the glucocorticoid receptor (GR) in T-cells
modified to express IL-13 zetakine for the treatment of glioblastoma.
Working with their clinical collaborator at the City of Hope National
Medical Center Sangamo expects to achieve preclinical proof of concept
of GR-modified T-cells in the first half of 2007 and to initiate a
Phase 1 trial by late in the second half of 2007.
* Sangamo expects to report data from the clinical programs in peripheral
artery disease recently acquired from Edwards Lifesciences and expects
to detail plans for these programs when the company reports its
financial results of the fourth quarter and year-end in February 2007.
* Sangamo also gave financial guidance for 2007 estimating that it expects
to end 2007 with approximately $35M in cash and cash equivalents, based
on current expense projections and expected progress in existing
corporate relationships.
The presentation from this week's Investor and Analyst Briefing will be archived on Sangamo's website until December 20, 2006 and is available at http://phx.corporate-ir.net/phoenix.zhtml?c=120938&p=irol-IRHome .
Today, SGMO and Dow announced achievement of multiple milestones. Here's what it means to SGMO.
In addition to the quarterly income of 500K + (1/12 of the 7.5 mil up front payment for the option) and the quarterly income of 300K for research funding we get some good portion of the 4 mil milestone pie.
When they exercise the option in 2 years or lesswe get 6 mil cash up front. As they launch each new product we get 20.5 mil per year + royalties.
This was almost sure to happen. Dow wouldn't expend 20 mil unless they were pretty sure it would result in viable products.
Dave
Sangamo BioSciences to Present Data From Its ZFP Therapeutic(TM) Programs at the 9th Annual Meeting of the American Society of Gene Therapy
ZFP Therapeutics Collaborator Chosen for ASGT 'Excellence in Research Award'
BALTIMORE, June 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced presentation of data from several of the Company's zinc finger DNA-binding protein (ZFP) Therapeutic(TM) programs at the 9th Annual Meeting of the American Society of Gene Therapy (ASGT). The meeting is being held in Baltimore, Maryland from May 31 through June 4, 2006.
Sangamo scientists and their collaborators will make a total of 9 podium and poster presentations covering several ZFP-mediated gene regulation and gene modification therapeutic programs. In addition, Sangamo collaborator Angelo Lombardo, from the San Raffaele Telethon Institute for Gene Therapy, Milan, Italy, was recognized with an Excellence in Research Award for his work described in an abstract entitled, "Towards Gene Correction of X-Linked SCID Using Engineered Zinc Finger Nucleases and Integrase Defective Lentiviral Delivery".
"The annual ASGT meeting provides an outstanding forum for sharing the latest developments in the field of gene therapy and, as in previous years, Sangamo has a significant presence," stated Edward Lanphier, Sangamo's president and CEO. "The breadth of material that we are presenting ranging from specific therapeutic programs to our internal research programs to refine and optimize our technology illustrates the potential broad utility of our science."
Philip Gregory, D.Phil., Vice President, Research at Sangamo noted, "We are presenting data for the first time on our process development progress in our ZFP Therapeutic program to disrupt the CCR5 gene for the potential treatment of HIV/AIDS. In a prize-winning abstract, our collaborators from the San Raffaele Telethon Institute in Milan will present data on the successful use of non-integrating vectors for delivery of our ZFNs for gene correction of X-linked SCID. In addition to updates across our ZFP Therapeutic programs in gene regulation, gene correction and gene disruption, several of our presentations are focused on technical advances and development of our proprietary ZFP nuclease (ZFN(TM)) technology. One presentation describes the use of our ZFN technology in targeted integration, which we believe has the potential to improve the safety, efficiency and utility of gene-based approaches for both therapeutic and enabling technology applications."
Sangamo scientists and their collaborators will make the following presentations; the abstract numbers, titles and a brief description of the data to be presented are listed below:
ZFP TF-mediated gene regulation
-- Abstract #788
Engineered Zinc Finger Protein Transcription Factors as a Potential
Therapy for Choriodal Neovascularization
Saturday, June 3, 2006. Oral Presentation.
Preclinical animal data will be presented from Sangamo's program to
develop ZFP TFs for the potential treatment of age-related macular
degeneration.
-- Abstract #1010
Developing a Potential Pain Therapy Using Engineered Zinc Finger
Protein Repressors of the Sodium Channel PN3
Saturday, June 3, 2006. Poster Presentation.
Data will be presented that demonstrate the successful use of ZFP TFs
to repress the expression of a well-validated pain receptor in primary
neuronal cells.
ZFN-mediated gene modification
-- Abstract # 555
Large-Scale, Flow-Based Electroporation To Deliver Engineered Zinc
Finger Protein Nucleases That Mediate High-Efficiency Disruption of the
Human CCR5 Gene
Friday, June 2, 2006. Poster Presentation.
Data will be presented demonstrating the efficient delivery of plasmid
to cells using a GMP compliant flow-based electroporation system.
-- Abstract # 738
Towards Gene Correction of X-Linked SCID Using Engineered Zinc Finger
Nucleases and Integrase Defective Lentiviral Delivery
Saturday, June 3, 2006. Oral Presentation.
-- Abstract # 758
Towards Gene Knock out Therapy for AIDS/HIV: Targeted Disruption of
CCR5 Using Engineered Zinc Finger Protein Nucleases (ZFNs)
Saturday, June 3, 2006. Oral Presentation.
-- Abstract # 787
Engineered Fok I Heterodimers for Enhanced Zinc Finger Nuclease
Specificity
Saturday, June 3, 2006. Oral Presentation.
Refinements of ZFN engineering will be presented that are designed to
enhance the specificity of action of ZFNs.
-- Abstract # 1003
Targeted Site-Specific Integration in Human Cells Using Designed Zinc
Finger Nucleases
Saturday, June 3, 2006. Poster Presentation.
Data will be presented demonstrating the application of ZFNs for
efficient targeted integration of DNA sequences.
-- Abstract # 1040
Towards Gene Correction Therapy for Wiskott-Aldrich Syndrome Using
Designed Zinc Finger Endonucleases
Saturday, June 3, 2006. Poster Presentation.
ZFP Applications
-- Abstract # 387
Advantageous Properties of the piggyBac Transposon System for Gene
Transfer in Human Cells
Friday, June 2, 2006. Oral Presentation.
Zinc Finger DNA-Binding Proteins
Zinc Finger DNA-binding Proteins (ZFPs) are a naturally occurring class of DNA binding proteins. The DNA recognition and binding function of ZFPs can be engineered and thus directed to a targeted sequence of DNA. This permits the delivery of a variety of functional domains to a gene-specific location. ZFPs are being developed for two significant therapeutic applications: gene regulation and gene modification. In the case of therapeutic gene regulation, ZFP transcription factors (ZFP TFs) are being engineered to either turn on therapeutically beneficial genes or turn off the expression of disease-causing genes. For gene modification, ZFPs are being used in combination with a DNA cutting enzyme (endonuclease) functional domain to generate ZFNs that facilitate the correction of mutant gene sequences that cause disease or the disruption of genes that facilitate disease progression.
About Sangamo
Sangamo BioSciences, Inc. is focused on the research and development of novel DNA-binding proteins for therapeutic gene regulation and modification. The most advanced ZFP Therapeutic(TM) development programs are currently in Phase 1 clinical trials for evaluation of safety in patients with diabetic neuropathy and peripheral artery disease. Other therapeutic development programs are focused on macular degeneration, ischemic heart disease, congestive heart failure, neuropathic pain, and infectious and monogenic diseases. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). By engineering ZFPs that recognize a specific DNA sequence Sangamo has created ZFP transcription factors (ZFP TF(TM)) that can control gene expression and, consequently, cell function. Sangamo is also developing sequence-specific ZFP Nucleases (ZFN(TM)) for therapeutic gene modification as a treatment for a variety of monogenic diseases, such as sickle cell anemia, and for infectious diseases, such as HIV. Sangamo has established several Enabling Technology Agreements with companies to apply its ZFP Technology to enhance the production of protein pharmaceuticals. Research at Sangamo is partially funded by an Advanced Technology Program (ATP) grant awarded by the National Institute of Standards and Technology (NIST). For more information about Sangamo, visit the company's web site at www.sangamo.com.
This press release may contain forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation, references to the research and development of novel ZFP TFs and ZFNs, clinical trials and therapeutic applications of Sangamo's ZFP technology platform. Actual results may differ materially from these forward-looking statements due to a number of factors, including technological challenges, Sangamo's ability to develop commercially viable products and technological developments by our competitors. See the company's SEC filings, and in particular, the risk factors described in the company's Annual Report on Form 10-K and its most recent 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.
SOURCE Sangamo BioSciences, Inc.
-0- 06/01/2006
/CONTACT: Elizabeth Wolffe, Ph.D. of Sangamo BioSciences, Inc.,
+1-510-970-6000, ext. 271, or ewolffe@sangamo.com; or media, Justin Jackson of
Burns McClellan, Inc., +1-212-213-0006, or jjackson@burnsmc.com, for Sangamo
BioSciences, Inc./
/Web site: http://www.sangamo.com/
(SGMO)
CO: Sangamo BioSciences, Inc.
ST: Maryland, California
IN: HEA BIO MTC
SU: TDS
JB
-- SFTH066 --
7869 06/01/2006 07:30 EDT http://www.prnewswire.com
However, a number of scientific papers in some very distinguished journals (Diabetes, Cell, etc.) have been published re: this therapeutic advance, and the fact that it has passed muster w/the FDA (stage 1 trials) gives it much more credence than other fly-by-night, "pump and dump" penny stocks...
Followers
|
85
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
878
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |